FDA Can Help On Drug Prices – Except When It Can't, Califf Says
This article was originally published in The Pink Sheet Daily
Commissioner nominee tells Senate that faster approvals of cheap products and quicker development of innovative ones will reduce pricing pressure; 'monopoly' positions are a concern, but Califf draws the line when asked about drug importation.
You may also be interested in...
In JAMA editorial, former FDA chief supports drug importation under narrow circumstances as a way to reduce drug prices, marking a shift from his previous stance on the issue and that of other past agency heads. Essay, co-authored by former CMS Acting Administrator Andy Slavitt, calls importation "a workaround born of desperation."
Upcoming House Oversight Committee hearing on drug pricing offers a chance for fireworks, but broader prospects for new Democratic pricing legislation seem limited.
Drug Importation Can Be Triggered By 'Excessive' Price Increases; Now US FDA Has To Decide What That Means
Did FDA Commissioner Scott Gottlieb and HHS Secretary Alex Azar have a change of heart on importation? Or are they being pressured from above?